Open Nav

Please submit your session questions in advance at

Fulcrum Therapeutics

  • Robert Gould, Fulcrum Therapeutics

Fulcrum is focused on small molecule therapeutics for diseases of gene misregulation. The company is creating therapeutics for a range of genetic disorders including: FSHD, Sickle Cell Disease, as well as other neuromuscular diseases. We plan to file our first IND in FSHD in 1H2019.

Fulcrum is founded on a precision medicine approach that integrates human genetics across the spectrum of drug discovery. Our integrated drug discovery approach has been productive by:

• focusing on the genetic root cause of the disease;

• creating accurate in vitro models using patient derived cellular models;

• using a combination of a curated gene regulation compound library, a CRISPR/Cas9 library and computational biology;

• and, developing genetic biomarkers to support an efficient path to the patient

  • Date:Monday, February 11
  • Time:1:15 PM - 1:30 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23356
  • Goal for Presentation:Update investors prior to next capital raise (<18mos)
  • Company
  • Company HQ City:Cambridge
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$140M
  • Size of Last Investment Round:$80M
  • Previous and Current Investors:Foresite, Third Rock Ventures, Fidelity, Casdin, 6 Dimension, Leerink, Section 32, Sanofi Ventures
  • CEO/Top Company Official:Robert Gould
  • Year Founded:2016
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development:FTX-1821 for fascioscapulohumeral dystrophy
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):1
Robert Gould
Fulcrum Therapeutics